hrp0089p2-p071 | Diabetes & Insulin P2 | ESPE2018

Clinical Details, Molecular Genetic Analysisand Clinical Pheonotype Correlation of 14 Patients with Neonatal Diabetes from The South India – A Single Centre Experience

Nagesh V Sri , Hattersley Andrew , Ellard Sian , Sethi Bipin , Franco Elisa De , Flanagan Sarah , Houghton Jayne , Venkateshwarlu M , Parekh Harsh , Dukle Vaibhav , Kelwade Jayant , Naseem Altaf , Kanithi Ravishankar , Nalli Ravi Kumar

Background: Neonatal diabetes mellitus (NDM) is a relatively rare form of monogenic diabetes and usually presents in the first 6–9 months of life. In this study, our objective was to report the clinical details, perform a detailed genetic analysis and acquire a clinical–phenotype correlation of our cohort.Materials and methods: NDM patients referred to SN Endocrine centre between period of Nov 2014 to April 2017 and patients under follow-up wit...

hrp0086p1-p235 | Diabetes P1 | ESPE2016

The Genetic Causes and Phenotypic Characteristics of Egyptian Patients with Neonatal Diabetes Mellitus

Elkaffas Rasha , Musa Noha , Franco Elisa De , Madani Hanan A , Shaalan Yomna , El-Kaffas Rania M.H. , Hassan Mona , Hafez Mona , Kholi Badawy El , Flanagan Sarah E , Ellard Sian , Hussain Khalid

Background: Neonatal Diabetes Mellitus (NDM) is a rare form of monogenic diabetes that typically presents during the first 6 months of life. Its prevalence is about 1:100 000 live births; however it may rise up to 1:29 000 in highly consanguineous populations. Mutations in 22 different genes are reported; with the most common cause being potassium channel subunit gene (KCNJ11/ABCC8) mutations. However, causative mutations among consanguineous populations seem to diffe...

hrp0094p1-197 | Thyroid B | ESPE2021

Management of newborns born to mothers with autoimmune hypothyroidism

Cavarzere Paolo , Palma Laura , Camilot Marta , Vincenzi Monica , Teofoli Francesca , Principe Lara Nicolussi , Gaudino Rossella , Murri Virginia , Pepaj Orsiol , Lubrano Luigi , Rossi Giuliana , Sallemi Alessia , Fattori Ermanna , Lauriola Silvana , Antoniazzi Franco ,

Background: Maternal autoimmune hypothyroidism can have negative consequences on the fetus: on the one hand, maternal hypothyrosinemia might affect the fetal brain development in the early stages of pregnancy; on the other, thyroid inhibiting antibodies can pass through the placenta. It is currently unclear if these antibodies may affect the newborn’s thyroid function. Consequently, there are no certain indications regarding the management of newborns bor...

hrp0086p2-p844 | Syndromes: Mechanisms and Management P2 | ESPE2016

Growth Screening in Children Aged Three to Five Years Seen in Community Paediatrics in Dreux District, France: Preliminary Results

Kayemba-Kay's Simon , Brin Isabelle , Nicot Florence , Maillet Odile , Roudiere Jean-Louis , Nicola Luigi Di , Heron Anne

Background: Over 90% children grow normally, and attain final height within their genetic target. Up to 10% of all children do not spontaneously catch-up by the age 3 years, besides some cases of TS are diagnosed late, and others with SGA go undiagnosed and unattended.Objectives & Hypothesis: Early screening of growth patterns in children attending Child Protection Visits (PMI, France) in Dreux district. Our objective was the evaluation of prevalence...

hrp0084p3-956 | GH & IGF | ESPE2015

A 5-year Follow-up of Adults, with Childhood-Onset GH Deficiency, Treated with GENOTONORM® in France

Touraine Philippe , Borson-Chazot Francoise , Delemer Brigitte , Brue Thierry

Background: Young adult patients with childhood-onset GH deficiency (GHD) whose GH replacement therapy (GHRT) is discontinued exhibit negative metabolic and physiological effects, reversible through GHRT.Objective and hypotheses: To report the characteristics and 5-year GHRT in adults with childhood-onset GHD.Method: Analysis of the subgroup of adults with childhood-onset GHD included between March 2003 and October 2006 in KIMS. In...

hrp0097rfc4.5 | Growth and syndromes (to include Turner syndrome) | ESPE2023

Real-world safety and effectiveness of vosoritide: Results from an early access program in France

Cormier-Daire Valérie , Edouard Thomas , Isidor Bertrand , Cohen Shelda , Mukherjee Swati , Pimenta Jeanne , Lhaneche Leila , Rossi Massimiliano , Schaefer Elise , Goodman Erin , Sigaudy Sabine , Baujat Geneviève

Introduction: Achondroplasia is the most common skeletal dysplasia, in which the main clinical feature is short stature. Vosoritide, the first specific treatment for achondroplasia; administered as a daily subcutaneous injection, was approved by the European Medicines Agency in August 2021 for patients aged ≥2 years until closure of epiphyses. French Health Authorities granted early access to vosoritide treatment in France on 24 June 2021, which continued u...

hrp0097p1-299 | GH and IGFs | ESPE2023

Real-world adherence to growth hormone treatment and catch-up growth in children with growth disorders in France: An interim analysis from the SCOPE study

Polak Michel , Bouhours-Nouet Natacha , Tauber Maithé , van Dommelen Paula , Khebbeb Sarah , Castello-Bridoux Claire , De Buyst Valerie , Koledova Ekaterina , Linglart Agnès

Background: The SCOPE French retrospective study follows children affected with growth hormone (GH) disorders treated with recombinant human GH (r-hGH) therapy via the easypod® connected injection device for up to 5 years.Aim: To show the results from an interim analysis of the SCOPE study analysing adherence to r-hGH therapy in a real-world setting and its effect on catch-up growth.Met...

hrp0095fc2.2 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Final heights in 398 patients with X-linked hypophosphatemia (XLH) over the last decades in France, a surrogate marker of improved disease management. Study of a large cohort of XLH patients born between 1950 and 2006.

Berkenou Jugurtha , Boros Emese , Amouroux Cyril , Bacchetta Justine , Briot Karine , Edouard Thomas , Gueorgieva Iva , Girerd Barbara , Kamenicky Peter , Lecoq Anne-Lise , Marquant Emeline , Mignot Brigitte , Porquet Bordes Valérie , Salles Jean-Pierre , Zhukouskaya Volha , Linglart Agnès , Rothenbuhler Anya

Introduction: XLH is caused by mutations in PHEX leading to increased FGF23 levels, phosphate wasting, and impaired endogenous calcitriol synthesis. Affected patients present with rickets and diminished growth velocity during childhood, and osteomalacia and short stature in adulthood. Adult height is linked with health within and across generations suggesting that adult height may be a potential tool for monitoring health conditions, e.g., XLH.<p ...

hrp0092p2-79 | Diabetes and Insulin | ESPE2019

Clinical Profile and Follow-up Analysis of Neonatal Diabetes Mellitus- Single Centre Experience

Korula Sophy , George Paul Praveen , Chapla Aaron , Mathai Sarah , Simon Anna

Aim: To study the clinical profile of Neonatal Diabetes Mellitus (NDM) at our centreObjectives: 1. To study follow-up data on growth, glycemic control2. To review genetic analysisIntroduction: NDM is rare and occurs at a frequency of 1:1,00,000. There is scarce literature on follow up of these patients although genetic data is well established (1). Developing...

hrp0084p2-335 | Fat | ESPE2015

Network Coordinated Primary Care Intervention in Obese Children and Adolescents: Almost a Decade of Experience

Guilmin-Crepon Sophie , Arsan Amine , Boizeau Priscilla , Alberti Corinne , Fidalgo Laurent , Chevallier Bertrand , Lubelski Patricia , Cheymol Jacques , Zaluski Alain , Tounian Patrick , Carel Jean-Claude , on behalf of REPOP Ile-de-France

Background: French health authorities have developed a national program to organize outpatient care networks for the prevention and management of obesity in children and adolescents (Réseau de Prise en Charge de l’Obésité Pédiatrique (REPOP)). To date, REPOP Ile-de-France has more than 250 primary care physicians with dietitians, nurses, educators, and psychologists trained in the management of childhood obesity as part of a standard care pathway, work...